Monotherapy with amlodipine or hydrochlorothiazide in patients with mild to moderate hypertension: Comparison of their efficacy and effects on electrolytes by Nwachukwu, Daniel C. et al.
Malawi Med J. 2017 Jun;29(2):108–112http://dx.doi.org/10.4314/mmj.v29i2.6
Malawi Medical Journal 29 (2): June 2017
Noncommunicable Diseases Special Issue Monotherapy with amlodipine or hydrochlorothiazide   108
© 2017 The College of  Medicine and the Medical Association of  Malawi. This work is licensed under the Creative Commons Attribution 4.0 International License.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)
Original Research
Monotherapy with amlodipine or hydrochlorothiazide 
in patients with mild to moderate hypertension: 
Comparison of their efficacy and effects on electrolytes
Daniel C. Nwachukwu1, Anthonius A. Eze2, Nkiru Z. Nwachukwu3, Eddy I. Aneke4, Polycarp U. 
Agu5, Nkiru C. Azubike6, Leonard F.O. Obika7, Onochie I. Okoye8
1. Department of  Physiology, College of  Medicine, University of  Nigeria, Enugu Campus, Enugu, Nigeria
2. Department of  Medical Biochemistry, College of  Medicine, University of  Nigeria, Enugu Campus, Enugu, Nigeria
3. Department of  Ophthalmolgy, University of  Nigeria Teaching Hospital, Enugu, Nigeria
4. Department of  Medicine, Enugu State University Teaching Hospital, Enugu, Nigeria
5. Department of  Obstetrics and Gynaecology, University of  Nigeria Teaching Hospital, Enugu, Nigeria
6. Department of  Medical Laboratory Science, College of  Medicine, University of  Nigeria, Enugu Campus, Enugu, Nigeria
7. Department of  Physiology, School of  Basic Medical Sciences, University of  Benin, Benin City, Nigeria
8. Department of  Ophthalmology, University of  Nigeria Teaching Hospital, Enugu, Nigeria
Correspondence: Dr Daniel C. Nwachukwu (daniel.nwachukwu@unn.edu.ng)
Introduction
Hypertension is a globally common condition that 
contributes to preventable disease and death.1 Essential 
hypertension is the most common cardiovascular disease 
among black Africans2 and it is also a significant cause of  
adult morbidity and mortality.3 The recommended initial 
treatment for hypertension in non-black subjects may involve 
the administration of  either angiotensin-converting enzyme 
(ACE) inhibitors, angiotensin receptor blockers (ARB), 
calcium channel blockers or  thiazide-type diuretic, while the 
recommended treatment for black hypertensive subjects was 
with either the calcium channel blockers (such as amlodipine) 
or with the thiazide-type diuretics (such as HCTZ).1 An 
earlier guideline recommended the use of  thiazide diuretics 
in the treatment of  uncomplicated hypertension, either as 
a monotherapy or in combination with other classes of  
anti-hypertensive drugs.4 However, a trial that evaluated this 
guideline found that a combination therapy with amlodipine 
was more efficacious at reducing blood pressure in high-
risk patients than a combination therapy with HCTZ.5,6 
Amlodipine and HCTZ are commonly prescribed in 
Nigeria as monotherapy and in combination with other 
antihypertensive drugs.7 Amlodipine monotherapy was 
reported to have achieved similar reduction in blood pressure 
in elderly patients as a combination therapy with HCTZ.8 
Similarly, a previous study among Nigerians with essential 
hypertension showed that amlodipine was a more effective 
than HCTZ in reducing blood pressure.7
Hydrochlorothiazide was reported to produce significant 
adverse effects on the potassium levels of  the subjects while 
amlodipine was neutra.l9 Hyponatremia and hypokalemia 
were observed during the initiation of  hydrochlorothiazide 
therapy in type 2 diabetic hypertensive Nigerian subjects, 
while amlodipine caused no significant clinical biochemical 
abnormality in their electrolyte profiles.7 The effects of  
amlodipine and HCTZ on electrolyte profile of  black 
patients with mild to moderate hypertension remain 
poorly understood. The present study investigated the 
efficacy and effects of  monotherapy with amlodipine or 
hydrochlorothiazide on the electrolyte profile of  Nigerians 
with mild to moderate hypertension.
Methods
Study location
The study was carried out in Enugu, the capital city of  Enugu 
state of  Nigeria. Enugu state is located in the South-East 
geopolitical zone of  Nigeria. Enugu city has a population of  
about a million people, mostly Nigerians of  the Igbo tribe. 
The inhabitants of  the city are mostly public servants, traders 
and artisans. The study lasted for a period of  5 months.
Abstract
Background
Amlodipine and hydrochlorothiazide (HCTZ) are commonly prescribed in Nigeria either as a monotherapy or in combination with other 
drugs. The present study was designed to investigate the antihypertensive efficacy of  monotherapy with amlodipine or HCTZ and their 
effects on electrolyte profile in patients with mild to moderate hypertension.
Methods
A single-blind randomized clinical study  was used; fifty patients newly diagnosed with mild to moderate hypertension (aged 33 to 60 
years) were recruited and divided into two groups:  amlodipine or hydrochlorothiazide each comprising of  25 subjects. The subjects 
received 5mg of  amlodipine or 25mg of  hydrochlorothiazide in their respective group once daily for 4 weeks. Blood pressure, serum and 
urine electrolytes were measured at baseline and weekly throughout the experiment.
Results
At the end of  follow up, amlodipine reduced systolic and diastolic blood pressure significantly more (p<0.001) than HCTZ. At the 
end of  follow up, blood pressure was reduced to normal in 80% of  the subjects in amlodipine group compared to 50% in HCTZ. 
Amlodipine had no significant effect on electrolyte profile of  subjects unlike HCTZ which significantly changed both their serum and 
urine electrolytes.
Conclusions
Monotherapy with amlodipine was more effective than HCTZ in black patients with mild to moderate hypertension and in addition 
maintained electrolyte balance.
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Sample size
This was estimated using the method of  Kadam and 
Bhalerao,10 as follows:
n = 2(Zα + Z1 – β)2σ2 where, 
                 Δ2
n is the required sample size,
Zα = 1.96 for 5% level of  significance,
Z1 – β = 0.84 at 80% statistical power,
σ = common standard deviation,
Δ = difference between mean values in a previous study.11
Fifty patients (28 males and 22 females) newly diagnosed 
with mild to moderate hypertension and aged between 33 
and 60 years attending the Medical Out-Patient clinic of  
EnuguState University Teaching Hospital, Enugu, were 
consecutively recruited into the study. However, one female 
subject withdrew from the study for non-medical reasons; 
only 49 subjects completed the study. The study was carried 
out in line with the guidelines of  the Helsinki Declaration 
for human studies, as amended and approved by the  Ethical 
Committee of  the Enugu State University Teaching Hospital 
(EC: ESUTTH/EC/11002).
Inclusion criteria
Consenting subjects newly diagnosed with mild to moderate 
hypertension using WHO guidelines.12 Mild hypertension is 
BP of  140-159/90-99mmHg while moderate is BP of  160-
179/100-109mmHg.
Exclusion criteria
Subjects with diabetes, chronic kidney disease, chronic heart 
disease, hepatic disease and cancer were excluded from 
the study. Pregnant women, individuals with evidence of  
secondary hypertension, chronic smokers and alcoholics 
were also excluded. 
Those that met the inclusion criteria were randomly divided 
into 2 groups (amlodipine and HCTZ). The group and 
treatment given were concealed from the physicians that 
took the measurements.
Group 1
Patients in this group were given 5mg amlodipine (Pfizer, 
New York, USA) once daily before breakfast for 4 weeks.
Group 2
Patients were given 25 mg HCTZ (Esidrex®, 
Novarvatis,Switzerland) once daily before breakfast for 4 
weeks.
Patients were given weekly appointments and a week worth 
of  medication during each visit. Treatment adherence was 
monitored every 2 days via phone calls and clinical evaluation 
carried out weekly on their appointment day.
Blood pressure, serum and urine electrolytes were measured 
at baseline and weekly during treatment for 4 weeks. 
Blood pressure measurement
Sitting BP was measured using Accoson® mercury 
sphygmomanometer. Two consecutive readings were taken 
from each subject at 5 minutes intervals and the average of  
these was calculated and taken as the mean blood pressure 
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Figure 1: Systolic blood pressure measurements following treatment with amlodipine and 
hydrochlorothiazide 
Each point on the graph represents the average of at least 25 independent measurements. Error 
bars are standard error of the mean; βP < 0.05, ββP < 0.01 (hydrochlorothiazide versus 





























Figure 2: Diastolic blood pressure measurements following treatment with amlodipine and 
hydrochlorothiazide	
Each point on the graph represents the average of at least 25 independent measurements. Error 
bars are standard error of the mean (SEM); βP < 0.05, ββP < 0.01 (hydrochlorothiazide versus 






























Figure 3: Mean arterial blood pressure measurements following treatment with amlodipine 
and hydrochlorothiazide 
Each point on the graph represents the average of at least 25 independent measurements. Error 
bars are standard error of the mean (SEM); ββP < 0.01 (hydrochlorothiazide versus amlodipine; 




























Figure 4: Serum Na+ measurements following with amlodipine and hydrochlorothiazide 
Each point on the graph represents the average of at least 25 independent measurements. Error 
bars are standard error of the mean (SEM); βββP < 0.001 (hydrochlorothiazide versus amlodipine; 





































Figure 1: Systolic blood pressure measurements following 
treatment w th amlodipine and hydrochlorothiazide
Each point on the graph represents the average of at least 25 independent 
measurements. Error bars are standard error of the mean; βP < 0.05, ββP < 0.01 
(hydrochlorothiazide versus amlodipine; two-way ANOVA with Bonferroni 
post-test, using Graphpad Prism 5.0).
Figure 3: Mean arterial blood pressure measurements following 
treatment with amlodipine and hydrochlorothiazide
Each p t on the g aph repr sents the average of at least 25 independent 
measur ments. E ror bars re standard error of t e me n (SEM); ββP < 0.01 
(hydrochlorothiazide versus amlodipine; two-way ANOVA with Bonferroni 
post-test, using Graphpad Prism 5.0).
Figure 2: Diastolic blood pressure measurements following 
treatment with amlodipine and hydrochlorothiazide
Each p i t on the graph repr sents the average of at least 25 independent 
measurements. Error bars are standard error of the mean (SEM); βP < 0.05, 
ββP < 0.01 (hydrochlorothiazide versus amlodipine; two-way ANOVA with 
Bonferroni post-test, using Graphpad Prism 5.0).
Figure 4: Serum Na+ measurements followi g with amlodipine 
and hydrochlorothiazide
Each point on the graph represents the average of at least 25 independent 
measurements. Error bars are standard error of the mean (SEM); βββP < 0.001 
(hydrochlorothiazide versus amlodipine; two-way ANOVA with Bonferroni 
post-test, using Graphpad Prism 5.0).
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baseline level. However, this difference was not significant 
throughout the duration of  the study (Figure 5). Amlodipine 
had no significant effect on serum Cl– while HCTZ 
significantly reduced it. When compared to each other, 
HCTZ significantly reduced serum Cl– at weeks 2 (p<0.01), 
3 (p<0.001) and 4 (p<0.001) (Figure 6).  
Amlodipine caused insignificant changes in urine electrolytes 
(Na+, K+ and Cl–) while HCTZ increased them. The changes 
in urine Na+ caused by HCTZ was significant at week 1 
(p<0.01) and weeks 2-4 (p<0.001) when compared to 
amlodipine (Figure 7); changes in K+ also followed a similar 
pattern (Figure 8) while that of  Cl– was significant at weeks 2 
(p<0.05), 3 (p<0.01) and 4 (p<0.001) (Figure 9). 
No adverse side effect was observed in both groups, however, 
polyuria was observed.
Discussion
Both amlodipine and HCTZ significantly reduced BP in 
mild to moderate hypertensive subjects. At the end of  follow 
up, blood pressure was reduced to normal in 80% of  the 
subjects in amlodipine group compared to 50% in HCTZ. 
The efficacy of  these drugs in the present study was higher 
than that earlier reported in a Nigerian population where 
monotherapy using 5 mg of  amlodipine daily achieved 40% 
reduction to normal BP while 25mg of  HCTZ daily produced 
35% reduction to normal BP.13 The increased efficacy seen 
in the present study may be due to shorter duration of  
treatment and adequate monitoring of  compliance via phone 
calls employed. Our study lasted for 4 weeks compared 
to 6 weeks in the above study and prolonged use of  these 
drugs has been shown to produce lower antihypertensive 
effect13; monitoring of  compliance was not indicated in the 
value. Readings were taken between 8.00 am and 10.00 am 
on their appointment. Any constrictive clothing on the arm 
was removed before measurement.
Serum electrolyte measurement
Venous blood (5 mL) was drawn from medial cubital vein 
into a vacutainer and allowed to coagulate for 25 minutes. 
The clot formed was removed by centrifuging at 2000 
rpm for 10 minutes. The resulting supernatant (serum) 
was removed for analysis. Serum electrolyte (Na+, K+, and 
Cl−) levels were determined by ion selective electrode using 
Audicom automated electrolyte analyzer (AC9000 series), 
China.
Urine electrolyte measurement
Urine samples were collected in clean containers and Na+, 
K+ and Cl−  measured using ion-selective electrode analyzer 
(Audicom automated electrolyte analyzer; AC9000 Series), 
China.
Statistical analysis
Results were presented as mean ± standard error of  mean. 
Data were classified by groups and weeks of  treatment 
and analyzed using SPSS Version 20 by IBM Corp. Two-
way analysis of  variance (ANOVA) was used to compare 
differences between groups, and further analysis was carried 
out using Bonferroni post-test (GraphPad prism 5.0). P 
values< 0.05 were considered significant.
Results
The mean age and BMI of  amlodipine and HCTZ groups 
were not significantly different (Table 1). Amlodipine 
reduced SBP, DBP and MAP at the end of  follow more than 
HCTZ group (Table 2). Amlodipine reduced SBP and DBP 
significantly more than HCTZ at weeks 3 and 4 and reduced 
MAP significantly more at week 4.
Amlodipine caused minimal changes in serum Na+ but HCTZ 
significantly reduced it; when both effects were compared 
to each other, the effect of  HCTZ was significantly higher 
(p<0.001) at weeks 2, 3 and 4 (Figure 4).  At the end of  
the follow up, amlodipine caused no change in serum K+ 
from baseline level whereas HCTZ reduced K+ from its 
Table 1: Patient demographic characteristics and body 
mass index (BMI)
Characteristic Amlodipine Hydrochlorothiazide




BMI (kg/m2) ± SD 27.44 ± 4.20 26.88 ± 3.40
SD = standard deviation
Table 2: Percentage change in blood pressure at the end of follow-up
% change in blood pressure at 
week 4
Amlodipine Hydrochlorothiazide
Systolic blood pressure (mmHg) ± 
standard deviation
–17.69 ± 3.12 –8.55 ± 1.64
Diastolic blood pressure (mmHg) 
± standard deviation
–12.36 ± 2.40 –5.22 ± 1.45
Mean arterial pressure (mmHg) ± 
standard deviation
–15.28 ± 2.31 –8.12 ± 2.15
Table 1: Patient demographic characteristics and body mass index
Table 2: Percentage change in blood pressure at the end of 
follow-up
!  
Figure 5: Serum K+ measurements following treatment with amlodipine and 
hydrochlorothiazide 
Each point on the graph represents the average of at least 25 independent measurements. Error 





































Figure 6: Serum Cl- measurements following treatment with amlodipine and 
hydrochlorothiazide 
Each point on the graph represents the average of at least 25 independent measurements. Error 
bars are standard error of the mean (SEM); ββP < 0.01, βββP < 0.001 (hydrochlorothiazide versus 






































Figure 5: Serum K+ measurements following treatment with 
amlodipine and hydrochlorothiazide
Each point on th  graph represents the average of at least 25 independent 
measurements. Error bars are standard error of the mean (SEM); generated using 
Graphpad Prism 5.0.
Figur  : Serum Cl– a urements following treatment with 
amlodipine and hydrochlorothiazide
Each point on the graph represents the average of at least 25 independent 
measurem nts. Error bars are sta dard error of the me n (SEM); generated using 
Graphpad Prism 5.0.
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Figure 9: Urine Cl- concentration following the administration of amlodipine and  
hydrochlorothiazide 
Each point on the graph represents the average of at least 25 independent measurements. Error 
bars are standard error of the mean (SEM); βP < 0.05, ββP < 0.01, βββP < 0.001 






































Figur : Urine Cl– concentration following the administration of 
amlodipine and  hydrochlorothiazide
Each point on the graph represents the average of at least 25 independent 
measurements. Error bars are standard error of the mean (SEM); βP < 0.05, ββP 
< 0.01, βββP < 0 01 (hydrochlorothiazide versus amlodipine; two-way ANOVA 
with Bonferroni post-test, using Graphpad prism 5.0).
studies.17,18 Treatment with HCTZ significantly increased 
urine electrolytes of  the subjects in the present study; this 
similar to earlier reports where HCTZ produced increase in 
urine electrolytes in patients with essential hypertension.7,18 
The corresponding increase in urine electrolytes suggests 
that they were lost from blood.
In conclusion, short-term monotherapy with amlodipine was 
more effective than hydrochlorothiazide in mild to moderate 
hypertensive Nigerians; it did not cause electrolyte imbalance 
unlike HCTZ. These results suggest that amlodipine may 
be safer as a monotherapy in black essential hypertensive 
subjects.
Recommendation
There is need to review the current management strategy 
in Nigeria where diuretics especially thiazide diuretics are 
mainly prescribed as the first line drugs in treatment of  
hypertension. Amlodipine should be the first line drug since 
it is more effective and did not cause electrolyte imbalance; it 
is also affordable just like hydrochlorothiazide.
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Figur : Urine Na+ concentration follo ing treatment with 
amlodipine and hydrochlorothiazide
Each point on the graph represents the average of at least 25 independent 
measurements. Error bars are standard error of the mean (SEM);  ββP < 0.01, 
βββP < 0.001 (hydrochlorothiazide versus amlodipine; two-way ANOVA with 
Bonferroni post-test, using Graphpad Prism 5.0).
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bars are standard error of the mean (SEM); ββP < 0.01, βββP < 0.001 (hydrochlorothiazide versus 





































Figure 8: Urine K+ concentration follo ing treatment with 
amlodipine n hydrochlorothiazide
Each point on the graph represents the average of at least 25 independent 
measurements. Error bars are standard error of the mean (SEM); ββP < 0.01, 
βββP < 0.001 (hydrochlorothiazide versus amlodipine; two-way ANOVA with 
Bonferroni post-test, using Graphpad Prism 5.0).
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